Desapriya Ediriweera: Aspirin and Cancer Prevention – Time to Update the Story
Desapriya Ediriweera, Research Associate at The University of British Columbia, shared a post on LinkedIn:
“Aspirin and Cancer Prevention: Time to Update the Story
For years, clinicians were taught that long‑term low‑dose aspirin could reduce colorectal cancer risk. Much of that belief came from pooled analyses of trials in middle‑aged adults, where benefits emerged only after 10–20 years of continuous use. It was a compelling narrative: a cheap, familiar drug offering both cardiovascular and cancer‑prevention benefits.
But the ASPREE trial and its extended follow‑up have fundamentally shifted that conversation for older adults.
In more than 19,000 healthy seniors (mean age ~75), aspirin showed:
- No reduction in overall cancer incidence
- No reduction in colorectal cancer incidence or mortality
- A 15% increase in cancer‑related mortality
- A possible reduction in melanoma and a possible increase in brain cancer-both based on small numbers
These findings echo a growing body of evidence: starting aspirin late in life does not prevent cancer and may cause harm. Biology makes sense. Older adults have higher rates of occult malignancy, different inflammatory pathways, and greater vulnerability to bleeding and competing risks.
The cardiovascular story has evolved in parallel. Modern trials show minimal primary‑prevention benefit and no mortality advantage for aspirin in most adults without established cardiovascular disease. Bleeding risk rises sharply with age. As a result, major guidelines now recommend against initiating aspirin for primary prevention in adults ≥60.
Where does aspirin still belong?
In secondary prevention-post‑MI, post‑stroke, and established atherosclerotic disease-where benefits remain clear and substantial.
The takeaway is simple and evidence‑based:
Aspirin is no longer a cancer‑prevention strategy for older adults, and its role in primary cardiovascular prevention has narrowed dramatically. Decisions about aspirin should be individualized, grounded in current data, and free from outdated assumptions.
As ASPREE reminds us, long‑held beliefs in medicine must evolve when the evidence does.
REF-Study Finds Surprising Link Between Aspirin in Seniors and Cancer Mortality-Longer follow-up of the ASPREE cohort is warranted, says researcher.”
Title: Effect of Aspirin on Cancer Incidence and Mortality in Older Adults
Authors: John J. McNeil, Peter Gibbs, Suzanne G. Orchard, Jessica E. Lockery, Wendy B. Bernstein, Yin Cao, Leslie Ford, Andrew Haydon, Brenda Kirpach, Finlay Macrae, Catriona McLean, Jeremy Millar, Anne M. Murray, Mark R. Nelson, Galina Polekhina, Christopher M. Reid, Ellen Richmond, Luz Maria Rodríguez, Raj C. Shah, Jeanne Tie, Asad Umar, G. J. van Londen, Kathlyn Ronaldson, Rory Wolfe, Robyn L. Woods, John Zalcberg, Andrew T. Chan
Read the Full Article on Journal of the National Cancer Institute
Stay updated with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience